(24/7 MARKET NEWS) – Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported, after yesterday’s market close, financial results for the fourth quarter and full year ended December 31, 2022, including sales of TAVALISSE tablets.
Highlights include;
• Fourth quarter 2022 Total Revenue of $51.3 million, including TAVALISSE net product sales of $21.9 million and REZLIDHIA net product sales of $0.9 million
• U.S. commercial launch of REZLIDHIA continues to progress and is supported by recent addition to NCCN Guidelines for AML
Rigel Pharmaceuticals is trading at $2.02, up $0.55 (+37.41%), on 1.8 million premarket shares.
Its 52-week trading range is $0.64 to $3.515. It’s just below its key $2.04 resistance level and, if it can break through that on strong volume, it has a few weaker resistance points to its 52 week high, but very doubtful that it gets there on this move.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
